Available vaccines in Europe
https://www.ecdc.europa.eu/en/seasonal-influenza/prevention-and-control/vaccines/types-of-seasonal-influenza-vaccine

Vaccine composition 

On 28 February 2020, WHO published recommendations for the components of influenza vaccines for use in the 2020–2021 northern hemisphere influenza season. 

Egg-based vaccines should contain the following: 

• an A/Guangdong-Maonan/SWL1536/2019 (H1N1)pdm09-like virus (Clade 6B.1A5A +187A); 
• an A/Hong Kong/2671/2019 (H3N2)-like virus (Clade 3C.2a1b+T135K-B); 
• a B/Washington/02/2019 (B/Victoria lineage)-like virus (Clade 1A(Δ3)B); and 
• a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus (Clade 3). 

Cell-based or recombinant-based vaccines should contain the following: 

• an A/Hawaii/70/2019 (H1N1)pdm09-like virus (Clade 6B.1A5A +187A); 
• an A/Hong Kong/45/2019 (H3N2)-like virus (Clade 3C.2a1b+T135K-B); 
• a B/Washington/02/2019 (B/Victoria lineage)-like virus (Clade 1A(Δ3)B); and 
• a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus (Clade 3). 

WHO recommended for use the 2020–2021 northern hemisphere influenza season that the influenza B virus component of both trivalent vaccine types in should be B/Washington/02/2019-like virus of the B/Victoria-lineage. 

The full report and Frequently Asked Questions for the 28 February 2020 decision are available on the WHO website. 

Based on WHO published recommendations on 25 September 2020, the composition of influenza vaccines for use in the 2021 southern hemisphere influenza season will contain the following:   

Egg-based vaccines  

• an A/Victoria/2570/2019 (H1N1)pdm09-like virus;  
• an A/Hong Kong/2671/2019 (H3N2)-like virus;  
• a B/Washington/02/2019 (B/Victoria lineage)-like virus; and  
• a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.  

Cell-based or recombinant-based vaccines  

• an A/Wisconsin/588/2019 (H1N1)pdm09-like virus;  
• an A/Hong Kong/45/2019 (H3N2)-like virus;  
• a B/Washington/02/2019 (B/Victoria lineage)-like virus; and  
• a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.  

It was recommended that the influenza B virus component of both trivalent vaccine types for use in the 2021 southern hemisphere influenza season should be a B/Washington/02/2019-like virus of the B/Victoria-lineage.  

The full report can be found here.  

On 26 February 2021, WHO published recommendations for the components of influenza vaccines for use in the 2021-2022 northern hemisphere influenza season:

Egg-based Vaccines

• an A/Victoria/2570/2019 (H1N1)pdm09-like virus;
• an A/Cambodia/e0826360/2020 (H3N2)-like virus;
• a B/Washington/02/2019 (B/Victoria lineage)-like virus; and
• a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

Cell- or recombinant-based Vaccines

• an A/Wisconsin/588/2019 (H1N1)pdm09-like virus;
• an A/Cambodia/e0826360/2020 (H3N2)-like virus;
• a B/Washington/02/2019 (B/Victoria lineage)-like virus; and
• a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

It was recommended that the influenza B virus component of both trivalent vaccine types for use in the 2021–2022 northern hemisphere influenza season should be a B/Washington/02/2019-like virus of the B/Victoria-lineage.